BioCrossroads

Lumavate, LLC operates a cloud-based software platform designed for manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their product labels into interactive channels, providing end-users with relevant information for repairs, access to authentic manufacturer parts, and support for services and technicians. Lumavate serves a diverse range of industries, including infrastructure (transportation and construction), outdoor sectors (agriculture, recreation, and landscaping), as well as industrial markets such as healthcare equipment and HVAC systems. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015. The platform focuses on building progressive web apps (PWAs) that facilitate highly personalized mobile experiences throughout the customer journey, promoting increased adoption and long-term engagement.

Kovina Therapeutics operates as a pre-clinical biotechnology company aims to discover a non-surgical, medical treatment for Human Papillomavirus (HPV) infections and cancers.

Novosteo Inc. develops and manufactures drugs to heal bone fractures. The company was founded in 2017 and is based in West Lafayette, Indiana.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.

Lumavate, LLC operates a cloud-based software platform designed for manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their product labels into interactive channels, providing end-users with relevant information for repairs, access to authentic manufacturer parts, and support for services and technicians. Lumavate serves a diverse range of industries, including infrastructure (transportation and construction), outdoor sectors (agriculture, recreation, and landscaping), as well as industrial markets such as healthcare equipment and HVAC systems. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015. The platform focuses on building progressive web apps (PWAs) that facilitate highly personalized mobile experiences throughout the customer journey, promoting increased adoption and long-term engagement.

OmniVis technology detects pathogens right at the source. Our easy-to-use hardware device and disposable test kit reduces the detection process to 30 minutes, accurately and affordably.

Scioto Biosciences, Inc. is focused on developing an Activated Bacterial Therapeutics (ABT) platform designed to deliver live therapeutic bacteria to the gut. This innovative platform allows for the delivery of active and live bacteria that can persist in the intestinal environment and adhere to the intestinal mucosa, thereby enhancing the effectiveness of microbiome-based treatments. Established in 2017 and headquartered in Indianapolis, Indiana, the company aims to transform the delivery of microbiome therapeutics, providing medical practitioners with advanced solutions to improve patient healing outcomes.

Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. The technology is based on the discovery by scientific founders Irina Petrache, MD, and Matthias Clauss, Ph.D. of a novel therapeutic target that plays a central role in the development and progression of lung disease.

SonarMed, Inc. provides solutions for the placement and monitoring of endotracheal tubes that are used in patients who cannot breathe on their own. Its SonarMed AirWave is a non invasive, adjunctive device that provides direct, precise, and real time monitoring of endotracheal tube position and function, which aids in detecting potentially dangerous or fatal endotracheal tube conditions. The company was founded in 2005 and is based in Carmel, Indiana.

Scioto Biosciences, Inc. is focused on developing an Activated Bacterial Therapeutics (ABT) platform designed to deliver live therapeutic bacteria to the gut. This innovative platform allows for the delivery of active and live bacteria that can persist in the intestinal environment and adhere to the intestinal mucosa, thereby enhancing the effectiveness of microbiome-based treatments. Established in 2017 and headquartered in Indianapolis, Indiana, the company aims to transform the delivery of microbiome therapeutics, providing medical practitioners with advanced solutions to improve patient healing outcomes.

SpeechVive is a medical technology company that specializes in providing a communication solution for people with Parkinson's Disease. It also specializes in the fields of healthcare, medical, and medical device manufacturing. The company was founded in 2011 and is headquartered in Lafayette, Indiana.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Apexian Pharmaceuticals, Inc., a clinical stage biotechnology company, develops novel compounds to treat cancer. Its lead drug candidate include APX3330, a oral anticancer agent that targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas, and others. Apexian Pharmaceuticals, Inc. was formerly known as ApeX Therapeutics, Inc. and changed its name to Apexian Pharmaceuticals, Inc. in October 2016. The company was founded in 2007 and is headquartered in Indianapolis, Indiana.

Diagnotes, Inc., a digital healthcare company, provides a platform to improve communication and collaboration for the healthcare industry. It offers Diagnotes, a clinical communication platform solution that is used for secure communication, provider scheduling, patient data, discussion documentation, patient engagement, and admin and reporting. The company's Diagnotes helps patients, physicians, care teams, hospitals, health systems, and physician practices to facilitate, track, and manage all patient-related communications. Diagnotes, Inc. was incorporated in 2010 and is based in Indianapolis, Indiana.

SonarMed, Inc. provides solutions for the placement and monitoring of endotracheal tubes that are used in patients who cannot breathe on their own. Its SonarMed AirWave is a non invasive, adjunctive device that provides direct, precise, and real time monitoring of endotracheal tube position and function, which aids in detecting potentially dangerous or fatal endotracheal tube conditions. The company was founded in 2005 and is based in Carmel, Indiana.

Bioscience Vaccines is a life-science company with proprietary adjuvant technology referred to as Matrix Immune Modulator and is based in the Purdue Research Park in West Lafayette, Ind. The company's products originated in the laboratory of Dr. Mark Suckow of the University of Notre Dame and are based on a technology discovered at Purdue University. The company's technology has the potential to be formulated as a companion product with vaccine products already approved and marketed for use by the FDA for the prevention of specific human and animal diseases.

ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung. The company was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients. It was incorporated in 2006 and is based in Indianapolis, Indiana.

FlowCo is a medical device company, develops products to improve the flow of blood through the vascular system.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.